4basebio launches high-performance enzymatic ssDNA platform to accelerate next-generation gene editing
4basebio has launched a new enzymatic single-stranded DNA platform designed to improve the manufacturing of gene editing therapies. The technology aims to replace traditional chemical synthesis to provide safer, more stable DNA templates for CRISPR applications.
Why it matters
Advancements in DNA manufacturing are critical for the scalability and safety of next-generation genetic medicines, potentially accelerating the path to clinical treatments.
4basebio launches high-performance enzymatic ssDNA platform to accelerate next-generation gene editing
The article is a standard industry announcement focusing on technical capabilities and business milestones.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in